Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Michael James Burke MD

Michael James Burke MD profile photo picture


Institution: Medical College of Wisconsin
Department: Pediatrics
Division: Hematology and Oncology - Pediatrics
Program: Oncology

Member of the Cancer Center

Leadership Positions

  • Leukemia & Lymphoma Program Director
  • Publications (69)

  • Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. (Schulte R, Hinson A, Huynh V, Breese EH, Pierro J, Rotz S, Mixon BA, McNeer JL, Burke MJ, Orgel E) Cancer Med 2021 Sep 16 PMID: 34528411 SCOPUS ID: 2-s2.0-85114952403 09/17/2021    
  • Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. (Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, Kahn JM, Chen J, Barth MJ, Magee JA, Gennarini L, Adhav AA, Clinton CM, Ocasio-Martinez N, Gotti G, Li Y, Lin S, Imamovic A, Tognon CE, Patel T, Faust HL, Contreras CF, Cremer A, Cortopassi WA, Garrido Ruiz D, Jacobson MP, Dharia NV, Su A, Robichaud AL, Saur Conway A, Tarlock K, Stieglitz E, Place AE, Puissant A, Hunger SP, Kim AS, Lindeman NI, Gore L, Janeway KA, Silverman LB, Tyner JW, Harris MH, Loh ML, Stegmaier K) Cancer Discov 2021 Jun;11(6):1424-1439 PMID: 33563661 PMCID: PMC8178162 SCOPUS ID: 2-s2.0-85107440371 02/11/2021       1 Citation
  • Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. (Rau RE, Dai Y, Devidas M, Rabin KR, Zweidler-McKay P, Angiolillo A, Schore RJ, Burke MJ, Salzer WL, Heerema NA, Carroll AJ, Winick NJ, Hunger SP, Raetz EA, Loh ML, Wood BL, Borowitz MJ) Pediatr Blood Cancer 2021 04;68(4):e28929 PMID: 33559396 SCOPUS ID: 2-s2.0-85100726475 02/10/2021    
  • Novel germline TRAF3IP3 mutation in a dyad with familial acute B lymphoblastic leukemia. (Pommert L, Burns R, Furumo Q, Pulakanti K, Brandt J, Burke MJ, Rao S) Cancer Rep (Hoboken) 2021 06;4(3):e1335 PMID: 33503336 PMCID: PMC8222551 SCOPUS ID: 2-s2.0-85099938449 01/28/2021    
  • Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. (Salzer WL, Burke MJ, Devidas M, Dai Y, Hardy KK, Kairalla JA, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP) J Clin Oncol 2020 08 10;38(23):2628-2638 PMID: 32496902 PMCID: PMC7402996 SCOPUS ID: 2-s2.0-85089203581 06/05/2020       6 Citations
  • Concurrent Imatinib Dosing With High-dose Methotrexate Leads to Acute Kidney Injury and Delayed Methotrexate Clearance in Pediatric Patients With Philadelphia Chromosome-positive B-Cell Acute Lymphoblastic Leukemia. (Pommert L, Liberio N, Ng JS, Egelund TA, Siver MJ, Katzenstein HM, Burke MJ) J Pediatr Hematol Oncol 2021 03 01;43(2):e296-e300 PMID: 32398599 SCOPUS ID: 2-s2.0-85085508892 05/14/2020       1 Citation
  • Isobaric Labeling Strategy Utilizing 4-Plex N,N-Dimethyl Leucine (DiLeu) Tags Reveals Proteomic Changes Induced by Chemotherapy in Cerebrospinal Fluid of Children with B-Cell Acute Lymphoblastic Leukemia. (Yu Q, Zhong X, Chen B, Feng Y, Ma M, Diamond CA, Voeller JS, Kim M, DeSantes KB, Capitini CM, Patel NJ, Hoover-Regan ML, Burke MJ, Janko K, Puccetti DM, Ikonomidou C, Li L) J Proteome Res 2020 07 02;19(7):2606-2616 PMID: 32396724 PMCID: PMC7334086 SCOPUS ID: 2-s2.0-85087529506 05/13/2020       3 Citations
  • Experience with ponatinib in paediatric patients with leukaemia. (Rossoff J, Huynh V, Rau RE, Macy ME, Sulis ML, Schultz KR, Burke MJ, Athale U, O'Brien MM, Gregory JJ Jr, van der Sluis IM, Keller FG, Zwaan CM, Suttorp M, Hijiya N) Br J Haematol 2020 04;189(2):363-368 PMID: 31975387 SCOPUS ID: 2-s2.0-85078788320 01/25/2020       7 Citations
  • Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. (Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA) Clin Cancer Res 2020 05 15;26(10):2297-2307 PMID: 31969338 PMCID: PMC7477726 SCOPUS ID: 2-s2.0-85084921034 01/24/2020       5 Citations
  • Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. (August KJ, Farooki S, Fulbright JM, August A, Portnoy JM, Pommert L, Burke MJ, Guest EM) Pediatr Blood Cancer 2020 01;67(1):e28021 PMID: 31571395 SCOPUS ID: 2-s2.0-85073970426 10/02/2019       3 Citations
  • Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. (Athale U, Hijiya N, Patterson BC, Bergsagel J, Andolina JR, Bittencourt H, Schultz KR, Burke MJ, Redell MS, Kolb EA, Johnston DL) Pediatr Blood Cancer 2019 09;66(9):e27827 PMID: 31330093 PMCID: PMC6944522 SCOPUS ID: 2-s2.0-85067390025 07/23/2019       14 Citations
  • Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. (Keating AK, Gossai N, Phillips CL, Maloney K, Campbell K, Doan A, Bhojwani D, Burke MJ, Verneris MR) Blood Adv 2019 07 09;3(13):1926-1929 PMID: 31243002 PMCID: PMC6616259 SCOPUS ID: 2-s2.0-85068800678 06/28/2019       22 Citations
  • What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy? (Taraseviciute A, Broglie L, Phelan R, Bhatt NS, Becktell K, Burke MJ) J Pediatr Hematol Oncol 2019 07;41(5):337-344 PMID: 30973486 SCOPUS ID: 2-s2.0-85064242570 04/12/2019       11 Citations
  • Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia. (Broglie L, Gershan J, Burke MJ) Int J Hematol Oncol 2019 Feb;8(1):IJH10 PMID: 30863527 PMCID: PMC6410023 03/14/2019    
  • Allogeneic Hematopoietic Cell Transplantation Provides No Benefit for Patients With Hypodiploid Acute Lymphoblastic Leukemia. (Burke MJ) J Clin Oncol 2019 04 01;37(10):763-764 PMID: 30794478 SCOPUS ID: 2-s2.0-85063972440 02/23/2019       1 Citation
  • Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. (Burke MJ, Salzer WL, Devidas M, Dai Y, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP) Haematologica 2019 05;104(5):986-992 PMID: 30545921 PMCID: PMC6518909 SCOPUS ID: 2-s2.0-85065494690 12/14/2018       10 Citations
  • Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia. (Andolina JR, Burke MJ, Hijiya N, Chaudhury S, Schultz KR, Roth ME) Biol Blood Marrow Transplant 2019 02;25(2):321-327 PMID: 30267760 SCOPUS ID: 2-s2.0-85056727740 09/30/2018       5 Citations
  • Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia. (Becktell K, Houser K, Burke MJ) J Pediatr Hematol Oncol 2019 01;41(1):e38-e40 PMID: 29668549 SCOPUS ID: 2-s2.0-85046027326 04/19/2018       6 Citations
  • Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. (Schulte RR, Madiwale MV, Flower A, Hochberg J, Burke MJ, McNeer JL, DuVall A, Bleyer A) Leuk Lymphoma 2018 10;59(10):2360-2368 PMID: 29431566 SCOPUS ID: 2-s2.0-85041894381 02/13/2018       9 Citations
  • Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. (Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, Borowitz M, Wood B, Heerema NA, Carroll AJ, Hilden JM, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP) Cancer 2018 03 15;124(6):1150-1159 PMID: 29266189 PMCID: PMC5839964 SCOPUS ID: 2-s2.0-85038428590 12/22/2017       15 Citations
  • Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group. (Bhojwani D, Burke MJ, Horton T, Ziegler DS, Sulis ML, Schultz KR, Wayne A, Izraeli S, Chang BH) Pediatr Hematol Oncol 2017 Sep - Oct;34(6-7):355-364 PMID: 29190164 PMCID: PMC6191173 SCOPUS ID: 2-s2.0-85035755135 12/01/2017       1 Citation
  • Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. (Burke MJ, Devidas M, Maloney K, Angiolillo A, Schore R, Dunsmore K, Larsen E, Mattano LA Jr, Salzer W, Winter SS, Carroll W, Winick NJ, Loh ML, Raetz E, Hunger SP, Bleyer A) Leuk Lymphoma 2018 07;59(7):1624-1633 PMID: 29115886 PMCID: PMC5940583 SCOPUS ID: 2-s2.0-85033406042 11/09/2017       17 Citations
  • Cohesin Mutations in Myeloid Malignancies. (Fisher JB, McNulty M, Burke MJ, Crispino JD, Rao S) Trends Cancer 2017 04;3(4):282-293 PMID: 28626802 PMCID: PMC5472227 SCOPUS ID: 2-s2.0-85016763591 06/20/2017       25 Citations
  • Administration of Dexrazoxane Improves Cardiac Indices in Children and Young Adults With Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes. (Schloemer NJ, Brickler M, Hoffmann R, Pan A, Simpson P, McFadden V, Block J, Tower RL 2nd, Burke MJ) J Pediatr Hematol Oncol 2017 07;39(5):e254-e258 PMID: 28452856 PMCID: PMC5591641 SCOPUS ID: 2-s2.0-85021364265 04/30/2017       10 Citations
  • Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. (Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, Chen IM, Valentine M, Liu Y, Li Y, Shao Y, Easton J, Payne-Turner D, Gu Z, Tran TH, Nguyen JV, Devidas M, Dai Y, Heerema NA, Carroll AJ 3rd, Raetz EA, Borowitz MJ, Wood BL, Angiolillo AL, Burke MJ, Salzer WL, Zweidler-McKay PA, Rabin KR, Carroll WL, Zhang J, Loh ML, Mullighan CG, Willman CL, Gastier-Foster JM, Hunger SP) Blood 2017 06 22;129(25):3352-3361 PMID: 28408464 PMCID: PMC5482101 SCOPUS ID: 2-s2.0-85021677684 04/15/2017       139 Citations
  • Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. (Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA Jr, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG) Nat Commun 2016 11 08;7:13331 PMID: 27824051 PMCID: PMC5105166 SCOPUS ID: 2-s2.0-84994404372 11/09/2016       109 Citations
  • Identification of High-risk Cryptic CRLF2 Rearrangements in B-Cell Acute Lymphoblastic Leukemia Utilizing an FGFR3/IGH Dual-Color Dual-Fusion DNA Probe Set. (Robin AJ, Peterson JF, Grignon JW Jr, Gheorghe G, Burke MJ, vanTuinen P) J Pediatr Hematol Oncol 2017 05;39(4):e207-e210 PMID: 27820126 SCOPUS ID: 2-s2.0-84994577405 11/08/2016       1 Citation
  • Oncolytic Seneca Valley Virus: past perspectives and future directions. (Burke MJ) Oncolytic Virother 2016;5:81-9 PMID: 27660749 PMCID: PMC5019429 09/24/2016    
  • Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia. (Burke MJ, Rheingold SR) Leuk Lymphoma 2017 03;58(3):540-551 PMID: 27546298 SCOPUS ID: 2-s2.0-84983048220 08/23/2016       17 Citations
  • Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia. (Sun W, Orgel E, Malvar J, Sposto R, Wilkes JJ, Gardner R, Tolbert VP, Smith A, Hur M, Hoffman J, Rheingold SR, Burke MJ, Wayne AS) Pediatr Blood Cancer 2016 11;63(11):1943-8 PMID: 27437864 PMCID: PMC7451261 SCOPUS ID: 2-s2.0-84988358055 07/21/2016       9 Citations
  • A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1. (Rodriguez V, Kairalla J, Salzer WL, Raetz EA, Loh ML, Carroll AJ, Heerema NA, Wood BL, Borowitz MJ, Burke MJ, Asselin BL, Devidas M, Winick NJ, Carroll WL, Hunger SP, Dreyer ZE) J Pediatr Hematol Oncol 2016 08;38(6):409-17 PMID: 27299599 PMCID: PMC4955695 SCOPUS ID: 2-s2.0-84974724296 06/15/2016       6 Citations
  • Minimal Residual Disease in NPM1-Mutated AML. (Burke MJ) N Engl J Med 2016 Feb 04;374(5):481-2 PMID: 26789634 SCOPUS ID: 2-s2.0-84956923873 01/21/2016       2 Citations
  • Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. (Lu BY, Thanawala SU, Zochowski KC, Burke MJ, Carroll WL, Bhatla T) Leuk Lymphoma 2016 08;57(8):1938-41 PMID: 26726842 SCOPUS ID: 2-s2.0-84953223472 01/05/2016       12 Citations
  • Emerging immunotherapy in pediatric lymphoma. (Erker C, Harker-Murray P, Burke MJ) Future Oncol 2016 Jan;12(2):257-70 PMID: 26616565 SCOPUS ID: 2-s2.0-84962769178 12/01/2015       3 Citations
  • Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. (Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Eldjerou L, Frangoul H, Guilcher GMT, Hayashi RJ, Ibrahim A, Kasow KA, Leung WH, Olsson RF, Pulsipher MA, Shah N, Shah NN, Thiel E, Talano JA, Kitko CL) Biol Blood Marrow Transplant 2015 Dec;21(12):2154-2159 PMID: 26327632 PMCID: PMC4654112 SCOPUS ID: 2-s2.0-84947443750 09/04/2015       16 Citations
  • Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. (Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM) Pediatr Blood Cancer 2015 May;62(5):743-50 PMID: 25307519 PMCID: PMC4376652 SCOPUS ID: 2-s2.0-84925352074 10/14/2014       38 Citations
  • How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. (Burke MJ) Future Oncol 2014 Dec;10(16):2615-27 PMID: 24983955 SCOPUS ID: 2-s2.0-84919791996 07/02/2014       26 Citations
  • A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. (Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR, Weigel BJ, Verneris MR, Miller JS) Am J Hematol 2014 Sep;89(9):889-95 PMID: 24891274 PMCID: PMC4134715 SCOPUS ID: 2-s2.0-84906100499 06/04/2014       66 Citations
  • Epigenetic modifications in pediatric acute lymphoblastic leukemia. (Burke MJ, Bhatla T) Front Pediatr 2014;2:42 PMID: 24860797 PMCID: PMC4030177 SCOPUS ID: 2-s2.0-84915754263 05/27/2014       31 Citations
  • A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD). (Gossai N, Verneris MR, Karras NA, Gorman MF, Patel NJ, Burke MJ) Bone Marrow Transplant 2014 Mar;49(3):440-2 PMID: 24317126 SCOPUS ID: 2-s2.0-84904242907 12/10/2013       8 Citations
  • Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation. (Burke MJ, Gossai N, Cao Q, Macmillan ML, Warlick E, Verneris MR) Bone Marrow Transplant 2014 Feb;49(2):174-8 PMID: 24185590 SCOPUS ID: 2-s2.0-84893790381 11/05/2013       15 Citations
  • Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population. (Pratt JA, Stricherz MK, Verghese PS, Burke MJ) Pediatr Blood Cancer 2014 Feb;61(2):366-8 PMID: 24038944 SCOPUS ID: 2-s2.0-84890874064 09/17/2013       27 Citations
  • How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. (Burke MJ, Burns L, Linden MA, Lindgren B, Verneris MR, Weisdorf D, Ustun C) Am J Hematol 2013 Sep;88(9):826-7 PMID: 23737091 PMCID: PMC3772519 SCOPUS ID: 2-s2.0-84882714075 06/06/2013       1 Citation
  • Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. (Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR) Biol Blood Marrow Transplant 2013 Jul;19(7):1021-5 PMID: 23567175 PMCID: PMC3712759 SCOPUS ID: 2-s2.0-84879339630 04/10/2013       19 Citations
  • Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS. (Smith AR, Christiansen EC, Wagner JE, Cao Q, MacMillan ML, Stefanski HE, Trotz BA, Burke MJ, Verneris MR) Pediatr Blood Cancer 2013 Apr;60(4):705-10 PMID: 23152304 PMCID: PMC3668778 SCOPUS ID: 2-s2.0-84873720700 11/16/2012       17 Citations
  • A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. (Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender J, Burke M, Weigel B, Stempak D, Balis FM, Blaney SM) Clin Cancer Res 2012 Nov 01;18(21):6011-22 PMID: 22962440 PMCID: PMC4008314 SCOPUS ID: 2-s2.0-84868543745 09/11/2012       87 Citations
  • Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. (Burke MJ, Gossai N, Wagner JE, Smith AR, Bachanova V, Cao Q, MacMillan ML, Stefanski HS, Weisdorf DJ, Verneris MR) Biol Blood Marrow Transplant 2013 Jan;19(1):138-42 PMID: 22960388 PMCID: PMC3530019 SCOPUS ID: 2-s2.0-84871918387 09/11/2012       24 Citations
  • Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. (Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P, Carroll WL) Blood 2012 May 31;119(22):5201-10 PMID: 22496163 PMCID: PMC3369610 SCOPUS ID: 2-s2.0-84861904198 04/13/2012       103 Citations
  • Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. (Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K, Singleton TP, Brunstein CG, Wagner JE, Verneris MR, Weisdorf DJ) Biol Blood Marrow Transplant 2012 Jun;18(6):963-8 PMID: 22430088 PMCID: PMC3631589 SCOPUS ID: 2-s2.0-84860796306 03/21/2012       28 Citations
  • Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes for children with B-precursor ALL and early or late BM relapse (Burke MJ, Verneris MR, Beck JC) Bone Marrow Transplantation December 2011;46(12):1571-1572 SCOPUS ID: 2-s2.0-84856115719 12/01/2011    
  • Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia. (Honebrink T, Dayton V, Burke MJ, Larsen K, Cao Q, Brunstein C, Weisdorf D, Miller JS, Wagner JE, Verneris MR) Biol Blood Marrow Transplant 2012 Jun;18(6):930-6 PMID: 22108570 PMCID: PMC4378716 SCOPUS ID: 2-s2.0-84860835017 11/24/2011       19 Citations
  • Treatment of relapsed acute lymphoblastic leukemia: approaches used by pediatric oncologists and bone marrow transplant physicians. (Burke MJ, Lindgen B, Verneris MR) Pediatr Blood Cancer 2012 Jun;58(6):840-5 PMID: 21796765 SCOPUS ID: 2-s2.0-84858685922 07/29/2011       4 Citations
  • Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. (Bachanova V, Sandhu K, Yohe S, Cao Q, Burke MJ, Verneris MR, Weisdorf D) Blood 2011 May 12;117(19):5261-3 PMID: 21403127 PMCID: PMC3109547 SCOPUS ID: 2-s2.0-79955976375 03/16/2011       10 Citations
  • Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. (Beck JC, Cao Q, Trotz B, Smith AR, Weigel BJ, Verneris MR, Burke MJ) Bone Marrow Transplant 2011 Jul;46(7):950-5 PMID: 20856210 SCOPUS ID: 2-s2.0-79960167283 09/22/2010       14 Citations
  • Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. (Burke MJ, Vogel RI, Janardan SK, Brunstein C, Smith AR, Miller JS, Weisdorf D, Wagner JE, Verneris MR) Biol Blood Marrow Transplant 2011 Jun;17(6):831-40 PMID: 20831896 PMCID: PMC3412271 SCOPUS ID: 2-s2.0-79956010659 09/14/2010       28 Citations
  • Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. (Shaw PJ, Kan F, Woo Ahn K, Spellman SR, Aljurf M, Ayas M, Burke M, Cairo MS, Chen AR, Davies SM, Frangoul H, Gajewski J, Gale RP, Godder K, Hale GA, Heemskerk MB, Horan J, Kamani N, Kasow KA, Chan KW, Lee SJ, Leung WH, Lewis VA, Miklos D, Oudshoorn M, Petersdorf EW, Ringdén O, Sanders J, Schultz KR, Seber A, Setterholm M, Wall DA, Yu L, Pulsipher MA) Blood 2010 Nov 11;116(19):4007-15 PMID: 20671124 PMCID: PMC2981549 SCOPUS ID: 2-s2.0-78149432602 07/31/2010       86 Citations
  • Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant. (Smith AR, Gulbahce E, Burke MJ, Cao Q, Macmillan ML, Tolar J, Orchard PJ, Blazar BR, Baker KS, Wagner JE, Verneris MR) Bone Marrow Transplant 2011 Mar;46(3):368-71 PMID: 20548337 PMCID: PMC3556271 SCOPUS ID: 2-s2.0-79952535218 06/16/2010       5 Citations
  • Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. (Verneris MR, Burke MJ) Curr Hematol Malig Rep 2010 Jul;5(3):157-62 PMID: 20446122 SCOPUS ID: 2-s2.0-77955980418 05/07/2010       3 Citations
  • Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. (Verneris MR, Eapen M, Duerst R, Carpenter PA, Burke MJ, Afanasyev BV, Cowan MJ, He W, Krance R, Li CK, Tan PL, Wagner JE, Davies SM) Biol Blood Marrow Transplant 2010 Sep;16(9):1237-44 PMID: 20302960 PMCID: PMC2904410 SCOPUS ID: 2-s2.0-77955512467 03/23/2010       31 Citations
  • Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim. (Beck JC, Burke MJ, Tolar J) Pediatr Blood Cancer 2010 Mar;54(3):490-1 PMID: 19908296 SCOPUS ID: 2-s2.0-76749161291 11/13/2009       20 Citations
  • Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). (Burke MJ, Cao Q, Trotz B, Weigel B, Kumar A, Smith A, Verneris MR) Pediatr Blood Cancer 2009 Dec 15;53(7):1289-94 PMID: 19731318 SCOPUS ID: 2-s2.0-70449711283 09/05/2009       23 Citations
  • Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. (Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE) Blood 2009 Nov 05;114(19):4293-9 PMID: 19706886 PMCID: PMC2774557 SCOPUS ID: 2-s2.0-77950404594 08/27/2009       226 Citations
  • The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. (Burke MJ, Willert J, Desai S, Kadota R) Pediatr Blood Cancer 2009 Dec;53(6):992-5 PMID: 19621426 SCOPUS ID: 2-s2.0-71049160882 07/22/2009       9 Citations
  • Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. (Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Aug;44(3):169-74 PMID: 19204709 SCOPUS ID: 2-s2.0-68949088557 02/11/2009       11 Citations
  • Treatment of a CNS relapse while on therapy for Burkitt lymphoma. (Burke MJ, Dayton V) Pediatr Blood Cancer 2009 Feb;52(2):290-2 PMID: 18937319 SCOPUS ID: 2-s2.0-59449110216 10/22/2008       2 Citations
  • Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. (Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Jan;43(2):107-13 PMID: 18776928 SCOPUS ID: 2-s2.0-59549085066 09/09/2008       43 Citations
  • Cardiac risks of imatinib in chronic myelogenous leukemia (CML) patients who receive allogeneic hematopoietic cell transplantation (Allo-HCT). (Burke MJ, Gursahaney A, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Michael VR) J Clin Oncol 2008 May 20;26(15_suppl):7039 PMID: 27949600 05/20/2008    
  • Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. (Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M) Pediatr Blood Cancer 2007 Aug;49(2):196-8 PMID: 17417796 SCOPUS ID: 2-s2.0-34447256148 04/10/2007       24 Citations
  • Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. (Burke MJ, Cohn SL) Pediatr Blood Cancer 2008 Mar;50(3):679-80 PMID: 16900484 SCOPUS ID: 2-s2.0-38549143161 08/11/2006       17 Citations
  • Last update: 10/11/2021